For example, in AML/MDS-MSCs, treatment with SD-208, an inhibitor of autocrine and paracrine TGF-β signaling [233], abrogates the suppressive effects of TGF-β1 on stromal cell functionality and restores the osteogenic differentiation capacity of patient-derived stromal cells [234]. This evidence concerns the gene TGFB1 and acute myeloid leukemia.